Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. (RILUZOX-01)

  • End date
    Apr 28, 2024
  • participants needed
  • sponsor
Updated on 12 July 2022


It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole versus placebo.

The trial population is composed of patients ≥18 years old that have developed stage II/III colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant chemotherapy.

The primary objective is to assess the preventive efficacy of riluzole on the severity of oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy of stage II/III colorectal cancers.

Condition Oxaliplatin-induced Peripheral Neuropathy
Treatment Placebo Oral Tablet, Riluzole
Clinical Study IdentifierNCT03722680
Last Modified on12 July 2022


Yes No Not Sure

Inclusion Criteria

Patients aged ≥ 18 years old
Eligible patient starting adjuvant oxaliplatin-based chemotherapy (6-12 cycles, Simplified FOLFOX4) for stage II/III colorectal cancer
Histological or cytological confirmation of colorectal cancer
Performance status (ECOG) ≤2
Normal hematological function (ANC ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L; hemoglobin ≥9.0 g/dL)
Normal hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome); aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤3 x ULN, and gamma-glutamyltransferase (GGT) ≤3 x ULN
Normal renal function: serum creatinine ≤1.5 x ULN
Normal cardiac function: ECG
Patients affiliated to the French national health insurance
Patient must have signed a written informed consent form prior to any study specific procedures
French language comprehension
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria

Metastatic cancer
Diagnosis of neuropathy
EORTC QLQ-CIPN20 sensory score >6
Previous neurotoxic chemotherapy treatment
Patients with chronic obstructive pulmonary disease
ALAT/ASAT elevated more than 3 times the normal value
Patients with known allergy or severe hypersensitivity to riluzole or any of the study drug excipients
Dependence on alcohol or drugs
Psychotic disorders
Women pregnant or breastfeeding
Patients undergoing a measure of legal protection (trusteeship, guardianship ...)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note